AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Gastrointestinal Parasites: Morantel tartrate is effective against various species of gastrointestinal nematodes, including roundworms such as Haemonchus contortus, Teladorsagia circumcincta, Trichostrongylus spp., and Oesophagostomum spp. It works by interfering with the nervous system of the parasites, causing paralysis and expulsion from the host animal's gastrointestinal tract.
Broad-Spectrum Activity: Morantel tartrate has broad-spectrum activity against both adult and larval stages of gastrointestinal nematodes. It is effective against both susceptible and some resistant strains of parasites, making it a valuable tool in parasite control programs for livestock.
Sheep and Goat Parasitism: Morantel tartrate is commonly used in sheep and goats to treat and control infections with gastrointestinal nematodes, which can cause weight loss, poor growth, anemia, diarrhea, and other symptoms in affected animals. Regular deworming with morantel tartrate can help prevent parasitic infestations and improve overall animal health and productivity.
Horse Parasitism: Morantel tartrate is also used in horses to treat and control infections with gastrointestinal parasites such as large and small strongyles, as well as pinworms. Regular deworming with morantel tartrate can help prevent parasitic-related health issues in horses, including colic, weight loss, and poor coat condition.
Safety and Tolerability: Morantel tartrate is generally safe and well-tolerated when used as directed. However, overdosing or misuse of the medication can lead to adverse effects such as gastrointestinal upset, including diarrhea and colic. It's essential to follow the dosage instructions provided by a veterinarian and to accurately estimate the weight of the animal being treated.
Resistance Management: Like other anthelmintic medications, resistance to morantel tartrate can develop in parasite populations over time with frequent and indiscriminate use. To minimize the risk of resistance, veterinarians may recommend implementing strategic deworming programs, rotating between different classes of anthelmintics, and conducting fecal egg count tests to monitor parasite burdens and drug efficacy.
Contraindications: Morantel tartrate should not be used in animals with known hypersensitivity to the drug or in animals intended for human consumption if the withdrawal period has not been observed. Pregnant and lactating animals should be treated with caution, and veterinary guidance should be sought before administering morantel tartrate to these animals.
Rank | Probiotic | Impact |
---|---|---|
species | Bacteroides uniformis | Increases |
species | Lacticaseibacillus paracasei | Reduces |
species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.3 | 0.2 | 0.5 |
ADHD | 1.9 | 0.6 | 2.17 |
Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
Allergic Rhinitis (Hay Fever) | 2.7 | 0.9 | 2 |
Allergies | 4.6 | 1.7 | 1.71 |
Allergy to milk products | 0.8 | 0.4 | 1 |
Alopecia (Hair Loss) | 1.3 | 1.3 | |
Alzheimer's disease | 2.5 | 5.2 | -1.08 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.3 | 4.33 |
Ankylosing spondylitis | 2.5 | 1.2 | 1.08 |
Anorexia Nervosa | 1.4 | 2.6 | -0.86 |
Antiphospholipid syndrome (APS) | 0.9 | 0.3 | 2 |
Asthma | 3.7 | 0.8 | 3.63 |
Atherosclerosis | 1.4 | 1.5 | -0.07 |
Atrial fibrillation | 3.2 | 1.9 | 0.68 |
Autism | 6.7 | 6.1 | 0.1 |
Autoimmune Disease | 0.3 | 0.7 | -1.33 |
Barrett esophagus cancer | 0.3 | -0.3 | |
benign prostatic hyperplasia | |||
Biofilm | 2 | 2 | |
Bipolar Disorder | 1.2 | 1.1 | 0.09 |
Brain Trauma | 0.3 | 0.8 | -1.67 |
Cancer (General) | 1.3 | -1.3 | |
Carcinoma | 2 | 1.4 | 0.43 |
Celiac Disease | 1.7 | 2 | -0.18 |
Cerebral Palsy | 1 | 1 | 0 |
Chronic Fatigue Syndrome | 2.8 | 6.2 | -1.21 |
Chronic Kidney Disease | 2.4 | 2.2 | 0.09 |
Chronic Lyme | 0.6 | 0.5 | 0.2 |
Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 1.4 | 0.64 |
Chronic Urticaria (Hives) | 0.5 | 1.2 | -1.4 |
Coagulation / Micro clot triggering bacteria | 1.2 | 1.3 | -0.08 |
Cognitive Function | 2.7 | 1 | 1.7 |
Colorectal Cancer | 4.6 | 1.3 | 2.54 |
Constipation | 0.8 | 0.7 | 0.14 |
Coronary artery disease | 1.5 | 2.2 | -0.47 |
COVID-19 | 4.2 | 8 | -0.9 |
Crohn's Disease | 5.1 | 4.2 | 0.21 |
Cushing's Syndrome (hypercortisolism) | 0.2 | -0.2 | |
cystic fibrosis | 0.5 | 0.7 | -0.4 |
deep vein thrombosis | 2.4 | 1.1 | 1.18 |
Denture Wearers Oral Shifts | 0.9 | 0.9 | |
Depression | 6.2 | 6.2 | 0 |
Dermatomyositis | 0.3 | 0.3 | |
Eczema | 1.1 | 1.7 | -0.55 |
Endometriosis | 1.7 | 1.4 | 0.21 |
Eosinophilic Esophagitis | 0.3 | -0.3 | |
Epilepsy | 1.6 | 1.2 | 0.33 |
erectile dysfunction | 0.8 | 0.8 | |
Fibromyalgia | 2.8 | 1.4 | 1 |
Functional constipation / chronic idiopathic constipation | 3.2 | 3.3 | -0.03 |
gallstone disease (gsd) | 3.3 | 0.5 | 5.6 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 1.2 | -0.5 |
Generalized anxiety disorder | 1.3 | 1.3 | 0 |
giant cell arteritis | 0.2 | -0.2 | |
Glioblastoma | 0.3 | -0.3 | |
Gout | 0.6 | 0.8 | -0.33 |
Graves' disease | 0.7 | 2.1 | -2 |
Gulf War Syndrome | 0.9 | 0.6 | 0.5 |
Halitosis | 0.3 | 0.3 | 0 |
Hashimoto's thyroiditis | 2.3 | 0.7 | 2.29 |
Heart Failure | 3.4 | 1.6 | 1.13 |
hemorrhagic stroke | 1 | 1 | |
Hidradenitis Suppurativa | 1.4 | 1.4 | |
High Histamine/low DAO | 1.3 | 0.3 | 3.33 |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
hyperglycemia | 0.6 | 0.6 | 0 |
Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
hypersomnia | 0.4 | -0.4 | |
hypertension (High Blood Pressure | 2.8 | 2.6 | 0.08 |
Hypothyroidism | 0.5 | 0.4 | 0.25 |
Hypoxia | 1.8 | 0.6 | 2 |
IgA nephropathy (IgAN) | 1.3 | 2.1 | -0.62 |
Inflammatory Bowel Disease | 4.2 | 7.2 | -0.71 |
Insomnia | 2.4 | 1.8 | 0.33 |
Intelligence | 0.5 | 0.9 | -0.8 |
Intracranial aneurysms | 0.9 | 0.3 | 2 |
Irritable Bowel Syndrome | 4.2 | 2.5 | 0.68 |
ischemic stroke | 1.7 | 0.8 | 1.13 |
Liver Cirrhosis | 4.5 | 2.5 | 0.8 |
Long COVID | 3.5 | 4.6 | -0.31 |
Low bone mineral density | 1.1 | -1.1 | |
Lung Cancer | 0.3 | 1 | -2.33 |
Mast Cell Issues / mastitis | 0.8 | 0.6 | 0.33 |
ME/CFS with IBS | 1.1 | 1.9 | -0.73 |
ME/CFS without IBS | 1.1 | 1.8 | -0.64 |
membranous nephropathy | 0.3 | 0.3 | |
Menopause | 0.3 | 0.5 | -0.67 |
Metabolic Syndrome | 5.1 | 3.9 | 0.31 |
Mood Disorders | 6 | 5.1 | 0.18 |
multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
Multiple Sclerosis | 4.2 | 6 | -0.43 |
Multiple system atrophy (MSA) | 0.6 | 0.4 | 0.5 |
myasthenia gravis | 0.3 | 0.7 | -1.33 |
neuropathic pain | 1.3 | -1.3 | |
Neuropathy (all types) | 0.4 | 1 | -1.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.9 | 2.8 | 0.04 |
NonCeliac Gluten Sensitivity | 0.1 | 0.1 | |
Obesity | 5.9 | 5.1 | 0.16 |
obsessive-compulsive disorder | 3.6 | 3.2 | 0.13 |
Osteoarthritis | 1.2 | 0.9 | 0.33 |
Osteoporosis | 1.1 | 1 | 0.1 |
pancreatic cancer | 0.3 | 0.3 | 0 |
Parkinson's Disease | 5.2 | 5.3 | -0.02 |
Polycystic ovary syndrome | 6 | 2.4 | 1.5 |
Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
primary biliary cholangitis | 1.1 | 0.5 | 1.2 |
Primary sclerosing cholangitis | 1.5 | 3.2 | -1.13 |
Psoriasis | 2.2 | 3.1 | -0.41 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.6 | 2.9 | 0.93 |
Rosacea | 0.5 | 0.7 | -0.4 |
Schizophrenia | 2.8 | 2.5 | 0.12 |
scoliosis | 0.3 | 0.7 | -1.33 |
sensorineural hearing loss | 0.5 | 0.5 | |
Sjögren syndrome | 1.7 | 1.4 | 0.21 |
Sleep Apnea | 2.1 | 1.3 | 0.62 |
Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 1.3 | 1.3 | |
Stress / posttraumatic stress disorder | 1.8 | 1.3 | 0.38 |
Systemic Lupus Erythematosus | 2.8 | 1.3 | 1.15 |
Tic Disorder | 0.8 | 1.2 | -0.5 |
Tourette syndrome | 0.9 | 0.9 | |
Type 1 Diabetes | 2.3 | 1.8 | 0.28 |
Type 2 Diabetes | 5.7 | 3.6 | 0.58 |
Ulcerative colitis | 3.6 | 4.1 | -0.14 |
Unhealthy Ageing | 4.2 | 1.9 | 1.21 |
Vitiligo | 1.9 | 1.2 | 0.58 |